Annexin V, Human Recombinant: Mechanistic, Benchmark-Driven Guide for Apoptosis and Coagulation Research

Executive Summary: Annexin V, human recombinant binds externalized phosphatidylserine (PS) on apoptotic cells in a strictly Ca²⁺-dependent manner, enabling sensitive early apoptosis detection (Biochem. J., 1994). The protein has a dissociation constant (Kd) of 15.5 ± 3.3 nM for PS-containing membranes under physiological conditions. Its use as an apoptosis detection reagent is supported by robust inhibition of procoagulant activity on endothelial cells with IC50 values in the low nanomolar range. APExBIO's Annexin V, human recombinant (SKU K2064) is supplied at 1 mg/mL in PBS (pH 7.4), ready for conjugation or direct use in apoptosis and coagulation assays (product page). This article clarifies boundaries, mechanistic rationale, and integration parameters for research workflows.

Biological Rationale

Annexin V is a member of the annexin superfamily of Ca²⁺-dependent phospholipid-binding proteins, with at least 13 family members identified in humans (Biochem. J., 1994). Under healthy physiological conditions, phosphatidylserine (PS) is confined to the inner leaflet of the plasma membrane. During early apoptosis, PS is rapidly translocated to the outer leaflet, serving as a signal for phagocytic removal of dying cells (Annexin V: Precision Apoptosis Detection). Annexin V binds selectively and with high affinity to PS in a Ca²⁺-dependent manner. Because PS externalization is an early and universal apoptosis marker, Annexin V has become the gold-standard probe for detection of apoptotic cells in cancer, immunology, and neurodegenerative disease models (Annexin V: Precise Early Apoptosis Marker). By masking PS, Annexin V also interferes with the assembly of coagulation complexes, supporting its use in coagulation research.

Mechanism of Action of Annexin V, human recombinant

Annexin V, human recombinant recognizes and binds PS exposed on the external membrane of cells undergoing apoptosis. This interaction is strictly dependent on the presence of millimolar concentrations of Ca²⁺ (typically 1–2 mM in assay buffers). The protein forms a two-dimensional lattice on PS-containing membranes, stabilizing its interaction and enabling high sensitivity for apoptotic cell detection. The dissociation constant (Kd) for recombinant human Annexin V binding to PS is 15.5 ± 3.3 nM, as measured on endothelial cells at physiological pH and temperature (Biochem. J., 1994). By competing with blood coagulation factors (e.g., prothrombin) for PS binding sites, Annexin V inhibits the assembly of prothrombinase and tenase complexes, reducing thrombin generation in vitro. In apoptosis detection assays, unlabeled Annexin V can be conjugated to fluorophores such as FITC, PE, or Cy3 to enable flow cytometry or microscopy-based analysis. See the Annexin V, human recombinant product page for reagent specifications and storage guidelines.

Evidence & Benchmarks

• Annexin V binds PS-positive membranes with Kd = 15.5 ± 3.3 nM at 37°C, pH 7.4, 1.5 mM Ca²⁺ (Biochem. J. 1994).
• The number of Annexin V binding sites on human umbilical vein endothelial cells (HUVEC) is ~8.8 × 10⁶ per cell under standard conditions (Biochem. J. 1994).
• Annexin V inhibits HUVEC-mediated thrombin formation with IC50 = 16 ± 12 nM, demonstrating potent anticoagulant activity in vitro (Biochem. J. 1994).
• Apoptotic cells detected by Annexin V-FITC or PE conjugates can be quantified by flow cytometry within minutes of PS externalization (Annexin V: Precise Early Apoptosis Marker).
• Annexin V, human recombinant (K2064) from APExBIO is validated for research use only and not for diagnostic procedures (APExBIO).

This article extends Annexin V: Precision Apoptosis Detection by providing updated quantitative binding parameters and workflow integration advice for the K2064 kit. For advanced mechanistic insights and competitive assay applications, see Annexin V, Human Recombinant: Mechanistic Insights, which is further clarified here with direct evidence and best-practice benchmarks.

Applications, Limits & Misconceptions

Annexin V, human recombinant is widely applied in:

• Early detection of apoptosis in mammalian cells via flow cytometry, microscopy, or plate-based assays.
• Competitive inhibition studies for phospholipase A1 and blood coagulation research.
• Cancer, immunology, and neurodegenerative disease modeling to quantify cell death dynamics (Annexin V: Advancing Early Apoptosis Detection; this article updates with specific usage parameters and storage guidelines).
• Assays utilizing fluorescent, biotinylated, or enzyme-conjugated Annexin V for multiplexed readouts.

Common Pitfalls or Misconceptions

• Annexin V binding is strictly Ca²⁺-dependent; omission of Ca²⁺ or use of chelators (e.g., EDTA) abolishes detection.
• Annexin V cannot distinguish apoptosis from necrosis if membrane integrity is compromised (use with PI or 7-AAD counterstaining for discrimination).
• Reagent is not intended for clinical diagnosis or therapeutic intervention—research use only (APExBIO).
• Non-specific binding may occur if PS is externalized by stress unrelated to apoptosis (e.g., mechanical damage, sample handling).
• Annexin V does not detect caspase activation or other non-PS apoptotic events; it is specific to PS externalization.

Workflow Integration & Parameters

APExBIO's Annexin V, human recombinant (K2064) is supplied as a 1 mg/mL liquid in PBS (pH 7.4), stored at -20°C for stability. Lyophilized forms can be reconstituted to 1–5 mg/mL in water or PBS. Prior to use, centrifuge vials briefly to ensure homogeneity. For apoptosis detection, conjugate the unlabeled protein to fluorophores (e.g., FITC, PE) or use in competition with labeled variants for assay optimization (Annexin V (SKU K2064): Scenario-Driven Solutions; this article emphasizes precise storage and dilution ranges for reproducibility). Typical working concentrations for cell staining are 1–5 μg/mL in binding buffer containing 1.5–2.5 mM Ca²⁺. For competitive or inhibition assays, titrate according to endpoint and cell model.

Conclusion & Outlook

Annexin V, human recombinant remains the benchmark apoptosis detection reagent and PS-binding probe for research applications. The K2064 kit from APExBIO enables robust, reproducible cell death analysis and mechanistic studies in cancer, neurodegeneration, and hematology. Future advances may include multiplexed detection with novel tags and integration with real-time, live-cell imaging. For further mechanistic and protocol optimization details, refer to the Annexin V, human recombinant product page and the referenced literature.